Amylyx Pharmaceuticals, Inc.: selling, general and administrative expense
Selling, general and administrative expense for Amylyx Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Amylyx Pharmaceuticals, Inc. financial histories
What this measure means
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
Exact concept: us-gaap:SellingGeneralAndAdministrativeExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 62,887,000 | USD | 2026-03-03 | 10-K · 0001193125-26-086645 |
| 2024-01-01 | 2024-12-31 | 114,331,000 | USD | 2026-03-03 | 10-K · 0001193125-26-086645 |
| 2023-01-01 | 2023-12-31 | 188,356,000 | USD | 2025-03-04 | 10-K · 0000950170-25-031309 |
| 2022-01-01 | 2022-12-31 | 127,128,000 | USD | 2024-02-22 | 10-K · 0000950170-24-018447 |
| 2021-01-01 | 2021-12-31 | 38,933,000 | USD | 2024-02-22 | 10-K · 0000950170-24-018447 |
Related financial histories
- Amylyx Pharmaceuticals, Inc.: total assets
- Amylyx Pharmaceuticals, Inc.: total liabilities
- Amylyx Pharmaceuticals, Inc.: stockholders equity
- Amylyx Pharmaceuticals, Inc.: cash and cash equivalents
- Amylyx Pharmaceuticals, Inc.: net income or loss
- Amylyx Pharmaceuticals, Inc.: operating cash flow
- Amylyx Pharmaceuticals, Inc.: capital expenditure payments
- Amylyx Pharmaceuticals, Inc.: revenue
- Amylyx Pharmaceuticals, Inc.: contract revenue excluding tax
- Amylyx Pharmaceuticals, Inc.: financing cash flow
- Amylyx Pharmaceuticals, Inc.: investing cash flow
- Amylyx Pharmaceuticals, Inc.: retained earnings or deficit
- Amylyx Pharmaceuticals, Inc.: basic weighted-average shares
- Amylyx Pharmaceuticals, Inc.: diluted weighted-average shares
- Amylyx Pharmaceuticals, Inc.: basic earnings per share
- Amylyx Pharmaceuticals, Inc.: diluted earnings per share
- Amylyx Pharmaceuticals, Inc.: income tax expense or benefit
- Amylyx Pharmaceuticals, Inc.: net property, plant and equipment
- Amylyx Pharmaceuticals, Inc.: share-based compensation expense
- Amylyx Pharmaceuticals, Inc.: operating income or loss
- Amylyx Pharmaceuticals, Inc.: current assets
- Amylyx Pharmaceuticals, Inc.: current liabilities
- Amylyx Pharmaceuticals, Inc.: current accounts payable
- Amylyx Pharmaceuticals, Inc.: net current accounts receivable
- Amylyx Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Amylyx Pharmaceuticals, Inc. / CIK 0001658551
- Captured
- 2026-09-21T17:22:12.113Z
- SEC response SHA-256
61333bff081cd95153f9c3b6a6d7088e53acd3f880438d3dc887c28126ad3c94
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001658551.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))